Stocks
Travere Therapeutics, Inc.TVTX
NASDAQHealthcareBiotechnology$51.25
Price as of · delayed, not real-time
A biopharmaceutical company focused on developing and commercializing therapies for rare kidney diseases. Its lead product, Filspari, targets IgA nephropathy, and the company is expanding its pipeline in other rare renal conditions. Investors track Travere for its commercial execution and regulatory milestones in a niche but high-need therapeutic area.
52W Range: $22.59-$68.73
Congressional Interest in Travere Therapeutics, Inc. (TVTX)
No congressional trades have been disclosed for Travere Therapeutics, Inc. (TVTX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TVTX?
No congressional trades found for this stock.